- Home
- RARE vs HIW Comparison
RARE vs HIW Comparison
Compare RARE & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- HIW
- Stock Information
- Founded
- RARE 2010
- HIW 1978
- Country
- RARE United States
- HIW United States
- Employees
- RARE N/A
- HIW N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- HIW Real Estate Investment Trusts
- Sector
- RARE Health Care
- HIW Real Estate
- Exchange
- RARE Nasdaq
- HIW Nasdaq
- Market Cap
- RARE 3.2B
- HIW 3.4B
- IPO Year
- RARE 2014
- HIW 1994
- Fundamental
- Price
- RARE $33.00
- HIW $29.15
- Analyst Decision
- RARE Strong Buy
- HIW Hold
- Analyst Count
- RARE 15
- HIW 7
- Target Price
- RARE $87.00
- HIW $31.00
- AVG Volume (30 Days)
- RARE 1.4M
- HIW 1.1M
- Earning Date
- RARE 11-04-2025
- HIW 10-28-2025
- Dividend Yield
- RARE N/A
- HIW 6.84%
- EPS Growth
- RARE N/A
- HIW N/A
- EPS
- RARE N/A
- HIW 1.16
- Revenue
- RARE $630,598,000.00
- HIW $811,773,000.00
- Revenue This Year
- RARE $19.65
- HIW N/A
- Revenue Next Year
- RARE $23.65
- HIW $5.19
- P/E Ratio
- RARE N/A
- HIW $25.23
- Revenue Growth
- RARE 20.63
- HIW N/A
- 52 Week Low
- RARE $25.81
- HIW $24.19
- 52 Week High
- RARE $53.04
- HIW $34.22
- Technical
- Relative Strength Index (RSI)
- RARE 52.70
- HIW 45.36
- Support Level
- RARE $29.36
- HIW $28.70
- Resistance Level
- RARE $35.95
- HIW $29.39
- Average True Range (ATR)
- RARE 1.60
- HIW 0.58
- MACD
- RARE -0.36
- HIW 0.06
- Stochastic Oscillator
- RARE 60.79
- HIW 63.68
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About HIW Highwoods Properties Inc.
Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.